The impact of PDE4 inhibitors on MMP expression and/or activity has been previously reported, mostly in the context of pulmonary diseases, in which these drugs abolish the enhanced elastolytic activity driven by inflammatory stimulus [47] and attenuate MMP-2 and/or MMP-9 levels [48,49]. The gene discussed is MMP2; the disease is lung disorder.